VIVORYON

VIVORYON

- EUR (-)

- 15 min delayed data - Euronext Amsterdam

Open:	-
Change:	-
Volume:	-

Low:	-
High:	-
High / Low range:	-

Type:	Stocks
Ticker:	VVY
ISIN:	NL00150002Q7

VIVORYON overview

> News GlobeNewsWire published a news.

Vivoryon Therapeutics N.V. to Present at the 2023 BIO CEO & Investor Conference • • GlobeNewsWire • Stocks • More VIVORYON news...

Vivoryon Therapeutics N.V. to Present at the 2023 BIO CEO & Investor Conference Halle (Saale) / Munich, Germany , February 3 , 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics, will present at the BIO CEO & Investor...

Thank you Chart

> Analyses

Londinia AI has published a new analysis.

0
42326
14198
0

VIVORYON - Daily

VIVORYON - Daily

Timeframe : Daily - Simple chart
Status : TARGET REACHED

VIVORYON is part of a very strong bullish trend. Traders may consider trading only long positions (at the time of purchase) as long as the price remains well above 11.38 EUR. The next resistance…

Thank you Reply Chart

> News EQS Group published a news.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference (CTAD) • • EQS Group • Stocks • More VIVORYON news...

EQS-News: Vivoryon Therapeutics N.V. / Key word(s): Conference Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference (CTAD) 28.11.2022 / 13:30 CET/CEST The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference...

Thank you Chart

> News EQS Group published a news.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares • • EQS Group • Stocks • More VIVORYON news...

EQS-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares (news with additional features) 23.11.2022 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA. Vivoryon Therapeutics Announces Successful Listing...

Thank you Chart

> News EQS Group published a news.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress • • EQS Group • Stocks • More VIVORYON news...

EQS-News: Vivoryon Therapeutics N.V. / Key word(s): 9 Month figures Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress (news with additional features) 22.11.2022 / 07:20 CET/CEST The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress HALLE (SAALE) / MUNICH, GERMANY, November 22, 2022 –...

Thank you Chart

> News EQS Group published a news.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022 • • EQS Group • Stocks • More VIVORYON news...

EQS-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022 14.11.2022 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022 HALLE (SAALE) / MUNICH, GERMANY, November 14, 2022 - Vivoryon Therapeutics N.V. (Euronext...

Thank you Chart

> News EQS Group published a news.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress • • EQS Group • Stocks • More VIVORYON news...

EQS-News: Vivoryon Therapeutics N.V. / Key word(s): Half Year Results Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress (news with additional features) 30.09.2022 / 08:47 CET/CEST The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress HALLE (SAALE) / MUNICH, GERMANY, September 30, 2022 – Vivoryon Therapeutics...

Thank you Chart

> News EQS Group published a news.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million • • EQS Group • Stocks • More VIVORYON news...

EQS-News: Vivoryon Therapeutics N.V. / Key word(s): Capital Increase Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million (news with additional features) 30.09.2022 / 08:45 CET/CEST The issuer is solely responsible for the content of this announcement. NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA. Vivoryon Therapeutics Announces...

Thank you Chart

Load more content

NEW !